Skip to main content
Jacobio Pharmaceuticals Group Co., Ltd. logo

Jacobio Pharmaceuticals Group Co., Ltd. — Investor Relations & Filings

Ticker · 1167 HKEX Manufacturing
Open in API
Filings indexed 298 across all filing types
Latest filing 2025-10-30 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1167

About Jacobio Pharmaceuticals Group Co., Ltd.

http://www.jacobiopharma.com

Jacobio Pharmaceuticals Group Co., Ltd. is a biopharmaceutical company specializing in the in-house discovery and development of innovative oncology therapies. The company is committed to providing breakthrough treatment solutions for patients by focusing its research and development pipeline on six major tumor signaling pathways: KRAS, Tumor Immunity, Tumor Metabolism, P53, RB, and MYC. Jacobio utilizes advanced drug discovery platforms, including induced allosteric mechanisms, to develop novel and improved medicines. The company primarily focuses on developing new drugs at the clinical stage, with the strategic goal of positioning its core projects among the top three globally in their respective therapeutic areas.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a formal disclosure under Hong Kong Stock Exchange listing rules detailing share repurchases and treasury share movements (FF305 Next Day Disclosure Return). It is not a generic financing update or earnings release, but a regulatory filing specifically reporting the company's own share transactions. This matches the definition for “Transaction in Own Shares” (POS).
2025-10-30 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares and treasury shares, including the repurchase of 132,000 shares on-market and the resulting balances. It is clearly reporting a share buyback/repurchase by the company (“transaction in own shares”), not an announcement of a new report or proxy materials, nor a full annual or interim report. Therefore, it falls under the category for share repurchase/own share transactions (Code: POS).
2025-10-30 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules, detailing the company’s repurchase of its own shares (treasury shares), closing/ opening balances of issued shares, and repurchase mandate details. This is clearly a report of transactions in the company’s own shares (share buybacks/treasury sales), matching the "Transaction in Own Shares" category.
2025-10-24 English
VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED PRECLINICAL DATA OF PAN-KRAS INHIBITOR JAB-23E73 AT THE AACR-NCI-EORTC 2025 INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on the Stock Exchange of Hong Kong about the company’s presentation of preclinical R&D data at a scientific conference. It does not report financial results (not ER or IR), is not an AGM or proxy statement, nor a capital raise, M&A, governance, or dividend notice. This type of miscellaneous announcement falls under the general Regulatory Filings fallback category (RNS).
2025-10-24 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Stock Exchange rules, detailing changes in issued shares and treasury shares, including a share repurchase transaction and on-market sale of treasury shares. This is a direct report of the company’s own share transactions (buybacks/treasury movement). Accordingly, it falls under the “Transaction in Own Shares” category.
2025-10-23 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a ‘Next Day Disclosure Return’ filed under Hong Kong Main Board Rule 13.25A/GEM Rule 17.27A providing detailed reporting of changes in issued shares, treasury shares, and share repurchases. It is not an earnings release, annual report, board change, or proxy statement, but specifically relates to buybacks and on‐market sales of treasury shares. This matches the ‘Transaction in Own Shares’ category.
2025-10-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.